The integration of cancer biomarkers into oncology has revolutionized cancer treatment,
yielding remarkable advancements in cancer therapeutics and the prognosis of cancer …

Although precision medicine has had a mixed impact on the clinical management of patients
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …

T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells,–.
Here we developed a clinical-grade approach based on CRISPR–Cas9 non-viral precision …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …

Therapeutic vaccines that elicit cytotoxic T cell responses targeting tumor-specific
neoantigens hold promise for providing long-term clinical benefit to patients with cancer …

Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …

Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for
cancer detection and intervention. Here, we use a machine learning model for detecting …

There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …

In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through
accurate assessment of minimal residual disease (MRD) and therapeutic response …

The continuous improvement in cancer care over the past decade has led to a gradual
decrease in cancer-related deaths. This is largely attributed to improved treatment and …